Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | CASP6 | P55212 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7584614 | 0.82 | CYP3A4 (0.70) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL10626656 | 0.82 | ESR1 (0.56) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL3825244 | 0.81 | CYP3A4 (0.68) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL3843730 | 0.79 | CYP3A4 (0.57) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL31680519 | 0.79 | CYP3A4 (1.00) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL3435311 | 0.79 | CYP3A4 (0.66) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL11305686 | 0.79 | SCN2A (0.60) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL1322530 | 0.79 | CYP3A4 (1.00) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL17104364 | 0.79 | SMN1; SMN2 (0.47) | MEN1KMT2AGAACASP6CYP3A4 | |
| SCHEMBL2549717 | 0.77 | MEN1 (0.73) | MEN1KMT2ACYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077930-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| US-6465455-B1 | TUMOUR NECROSIS FACTOR AND INTERLEUKIN FAMILY INHIBITORS; INHIBITION OF ENZYME P38 KINASE; INFLAMMATION, IMMUNO-REGULATION, ALLERGIES | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1077930-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059960-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |